Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 3
1955 1
1956 2
1957 2
1958 5
1959 2
1960 1
1961 1
1962 1
1963 1
1964 2
1965 1
1966 2
1967 4
1968 2
1969 7
1970 6
1971 6
1972 8
1973 5
1974 3
1975 1
1976 1
1977 1
1978 5
1979 8
1980 7
1981 8
1982 9
1983 4
1984 4
1985 7
1986 11
1987 2
1988 8
1989 6
1990 8
1991 5
1992 12
1993 10
1994 17
1995 19
1996 18
1997 16
1998 20
1999 26
2000 24
2001 27
2002 25
2003 28
2004 25
2005 24
2006 23
2007 25
2008 17
2009 18
2010 20
2011 19
2012 23
2013 18
2014 21
2015 23
2016 27
2017 17
2018 18
2019 21
2020 16
2021 14
2022 20
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

761 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: bergeron j. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: bergeron j. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E. Witztum JL, et al. Among authors: bergeron j. N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944. N Engl J Med. 2019. PMID: 31390500 Clinical Trial.
A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling.
Alphonse N, Wanford JJ, Voak AA, Gay J, Venkhaya S, Burroughs O, Mathew S, Lee T, Evans SL, Zhao W, Frowde K, Alrehaili A, Dickenson RE, Munk M, Panina S, Mahmood IF, Llorian M, Stanifer ML, Boulant S, Berchtold MW, Bergeron JRC, Wack A, Lesser CF, Odendall C. Alphonse N, et al. Among authors: bergeron jrc. Cell. 2022 Jun 23;185(13):2354-2369.e17. doi: 10.1016/j.cell.2022.04.028. Epub 2022 May 13. Cell. 2022. PMID: 35568036 Free PMC article.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Robinson JG, et al. Among authors: bergeron j. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Free article. Clinical Trial.
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, Moriarty PM, Rubba P, Whitcomb DC, Banerjee P, Gewitz A, Gonzaga-Jauregui C, McGinniss J, Ponda MP, Pordy R, Zhao J, Rader DJ. Rosenson RS, et al. Among authors: bergeron j. Nat Med. 2023 Mar;29(3):729-737. doi: 10.1038/s41591-023-02222-w. Epub 2023 Mar 6. Nat Med. 2023. PMID: 36879129 Free PMC article. Clinical Trial.
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D; HAUSER-RCT Investigators. Santos RD, et al. Among authors: bergeron j. N Engl J Med. 2020 Oct 1;383(14):1317-1327. doi: 10.1056/NEJMoa2019910. Epub 2020 Aug 29. N Engl J Med. 2020. PMID: 32865373 Clinical Trial.
Athletes with disabilities.
Bergeron JW. Bergeron JW. Phys Med Rehabil Clin N Am. 1999 Feb;10(1):213-28, viii. Phys Med Rehabil Clin N Am. 1999. PMID: 10081061 Review.
Zygomatic Arch Fracture.
Bergeron JM, Raggio BS. Bergeron JM, et al. 2024 Jan 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Jan 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31751088 Free Books & Documents.
761 results